-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-207 in Gliosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Gliosarcoma Drug Details: G-207 is under development for medulloblastoma, primitive neuroectodermal tumor, ependymoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-001 in Osteoarthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.G-001 in OsteoarthritisDrug Details:G-001 is under development for the treatment of knee osteoarthritis. The drug candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rexin-G in Osteosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rexin-G in Osteosarcoma Drug Details: Rexin-G is under development for the treatment of chondrosarcoma, chordoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rexin-G in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rexin-G in Breast Cancer Drug Details: Rexin-G is under development for the treatment of chondrosarcoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-207 in Anaplastic Astrocytoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Anaplastic Astrocytoma Drug Details: G-207 is under development for medulloblastoma, primitive neuroectodermal tumor,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-207 in Recurrent Medulloblastoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Recurrent Medulloblastoma Drug Details: G-207 is under development for medulloblastoma, primitive neuroectodermal tumor,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-100 in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.G-100 in Follicular Lymphoma Drug Details: G-100 (ID-G100) is under development for the treatment of Merkel...
-
Product Insights
![]()
K12-G Field, Netherlands
K12-G upstream field is located in North Sea, Netherlands. The upstream field is owned by EBN BV (30%); Neptune Energy Netherlands BV (49.29%); ONE-Dyas BV (2.84%); Production North Sea Netherlands Ltd (10%); Rosewood Exploration Ltd (Inactive) (2.83%); XTO Netherlands Ltd (5.04%). It is operated by Neptune Energy Netherlands BV. The project started its operations in 2002. K12-G Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2,...
-
Product Insights
![]()
L04-G Field, Netherlands
L04-G upstream field is located in North Sea, Netherlands. The upstream field is owned by EBN BV (40%); Total E&P Netherlands BV (55.66%); Vermilion Energy Netherlands BV (4.34%). It is operated by Total E&P Netherlands BV. The project started its operations in 2006. L04-G Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end...
-
Product Insights
![]()
K06-G Field, Netherlands
K06-G upstream field is located in North Sea, Netherlands. The upstream field is owned by EBN BV (40%); Total E&P Netherlands BV (56.16%); Vermilion Energy Netherlands BV (3.84%). It is operated by Total E&P Netherlands BV. The project started its operations in 1999. K06-G Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-207 in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Glioblastoma Multiforme (GBM) Drug Details: G-207 is under development for medulloblastoma, primitive neuroectodermal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-100 in Merkel Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.G-100 in Merkel Cell CarcinomaDrug Details: G-100 (ID-G100) is under development for the treatment of Merkel...
-
Product Insights
![]()
Gannet G Field, United Kingdom
Gannet G upstream field is located in North Sea, United Kingdom. The upstream field is owned by Neo Energy (SNS) Ltd (50%); Shell U.K. Ltd (50%). It is operated by Shell U.K. Ltd. The project started its operations in 1999. Gannet G Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves...
-
Company Insights
![]()
Legal and General (L&G) – Digital Transformation Strategies
Legal & General (L&G) Digital Transformation Strategies Report Overview Legal & General (L&G) has been focusing on emerging technologies as a part of its digital transformation strategies. The annual ICT spending of L&G was estimated at $391.9 million in 2022. A major share of this spending is earmarked for acquiring software, hardware, and consulting from vendors. L&G provides insurance, saving, and investment products, it offers individual and group protection plans, annuities, mortgages, pension plans, and general insurance products. Total ICT...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-207 in Atypical Teratoid Rhabdoid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Atypical Teratoid Rhabdoid Tumor Drug Details: G-207 is under development for medulloblastoma, primitive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-100 in Marginal Zone B-cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.G-100 in Marginal Zone B-cell Lymphoma Drug Details: G-100 (ID-G100) is under development for the treatment...
-
Company Profile
![]()
KT&G Corp – Company Profile
KT&G Corp (KT&G) produces, distributes and sells tobacco, ginseng, health food, cosmetics and pharmaceuticals products. The company's products portfolio consists of red ginseng, food and beverages, over-the-counter medicines and medical supplies and equipment's. It also distributes materials related to tobacco business. KT&G markets these products under various brands including, Esse, Carnival, Bohem, Raison, This, Tonino Lamborghini, Time, and Pine. It is also involved in real estate, rental and house development business, leaf tobacco cultivation and trading related activities. The company...
Add to Basket -
Company Profile
![]()
G M Breweries Ltd – Company Profile
G M Breweries Ltd (GMBL) is a manufacturer and marketer of alcoholic beverages. The company's product portfolio comprises country liquor and Indian made foreign liquor. GMBL markets its products under the G.M. Doctor, G.M. Santra, G.M. Limbu Punch and G.M. Dilbahar Sounf brand names. The company offers liquors in different sizes of bottles and in PET bottles. GMBL manufactures liquors in various flavors, including lime, lemon, orange, sugarcane, herb and spice. The company manufactures country liquor in Maharashtra state of...
Add to Basket -
Product Insights
![]()
McArthur River Unit (Middle Kenai G) Field, United States
McArthur River Unit (Middle Kenai G) upstream field is located in Alaska, United States. The upstream field is owned by Hilcorp Alaska LLC. It is operated by Hilcorp Alaska LLC. The project started its operations in 2009. McArthur River Unit (Middle Kenai G) Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years,...
-
Sector Analysis
New![]()
Automotive Heavy Trucks Market Trends and Analysis by Technology, Companies and Forecast to 2028
Automotive Heavy Trucks Market Overview The automotive heavy trucks market is valued at 3.1 million units in 2023 and is expected to record a CAGR of more than 3% during 2023-2028. Due to new product introductions, partnerships between engine manufacturers and mining equipment OEMs, and capacity growth by the top OEMs, the market for electric heavy-duty trucks is anticipated to grow. A big push for the adoption of electric heavy-duty trucks worldwide is also being provided by significant contracts between...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.